NCT05039060 is a NA clinical trial of Modified MAC diet (3-weeks) in Colorectal Cancer, sponsored by Korea University Anam Hospital.

Who is sponsoring NCT05039060?

NCT05039060 is sponsored by Korea University Anam Hospital.

What drugs are being tested in NCT05039060?

Interventions in NCT05039060: Modified MAC diet (3-weeks).

What condition does NCT05039060 study?

NCT05039060 studies Colorectal Cancer, Gut Microbiota, Diet Intervention.

Is NCT05039060 still recruiting?

NCT05039060 is currently status unknown. Last updated 9 September 2021.

Last reviewed 2021-09-09 · How we verify

NCT05039060

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Modified MAC Diet and Gut Microbiota in CRC Patients

Status unknown NA Last updated 9 September 2021

What this trial tests

NA trial testing Modified MAC diet (3-weeks) in Colorectal Cancer in 40 participants. Status unknown.

Timeline

1 September 2021

Primary endpoint
30 November 2022

28 February 2023

Quick facts

Lead sponsor	Korea University Anam Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 September 2021
Primary completion	30 November 2022
Estimated completion	28 February 2023
Sites	1 location across South Korea

Drugs / interventions tested

Modified MAC diet (3-weeks)

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →
Gut Microbiota — all drugs for Gut Microbiota →
Diet Intervention — all drugs for Diet Intervention →

Sponsor

Korea University Anam Hospital

Who can join

19 and older, any sex, with Colorectal Cancer or Gut Microbiota. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the changes in the composition and diversity of intestinal microbiota during 3-weeks of modified MAC diet and conventional diet in stage I or low-risk stage II colorectal cancer (CRC) patients after surgery. Additionally, the investigator analyze the association of gut microbiota and stool formation pattern or quality of life according to dietary pattern. Therefore, the investigator identify the beneficial or harmful microbiota composition and diversity adapting modified MAC diet that related to cancer recurrence, which provide supporting evidence for future prospective trial.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic (Review).
Sun J, Chen S, Zang D, Sun H, et al · · 2024 · cited 71× · PMID 38426581 · DOI 10.3892/ijo.2024.5632
Bidirectional effects of intestinal microbiota and antibiotics: a new strategy for colorectal cancer treatment and prevention.
Zhang W, Zhang J, Liu T, Xing J, et al · · 2022 · cited 10× · PMID 35661254 · DOI 10.1007/s00432-022-04081-3
Beneficial microbiome and diet interplay in early-onset colorectal cancer.
Zhou Z, Kleis L, Depetris-Chauvin A, Jaskulski S, et al · · 2025 · cited 8× · PMID 39653811 · DOI 10.1038/s44321-024-00177-0
The impact of a modified microbiota-accessible carbohydrate diet on gut microbiome and clinical symptoms in colorectal cancer patients following surgical resection.
Kim B, Lee J, Jung ES, Lee S, et al · · 2024 · cited 2× · PMID 38380099 · DOI 10.3389/fmicb.2024.1282932
Exploring the role of gut microbiota in colorectal liver metastasis through the gut-liver axis.
Liu QL, Zhou H, Wang Z, Chen Y. · · 2025 · cited 1× · PMID 40181829 · DOI 10.3389/fcell.2025.1563184

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Korea University Anam Hospital trials

Trials by the same sponsor.

NCT07510932 — Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients · Phase 2 · not yet recruiting
NCT07280780 — CGM-Based Glycemic Analysis After ESI · not yet recruiting
NCT07189000 — Patient-centered REhabilitation Program to Advance REcovery · NA · not yet recruiting
NCT07246148 — NOn-inVAsive Blood Pressure Monitoring in Intracranial Aneurysm Embolization · NA · recruiting
NCT07376980 — The SMART Trial: Modified Single-Stapled Anastomosis in Laparoscopic or Robotic Low Anterior Resection for Rectal Cancer · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05039060 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Korea University Anam Hospital
Last refreshed: 9 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05039060.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing